CAT 179
Alternative Names: CAT-179Latest Information Update: 30 Jun 2023
At a glance
- Originator Catamaran Bio
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Breast cancer; Gastric cancer; Ovarian cancer
Most Recent Events
- 14 Apr 2023 Preclinical trials in Ovarian cancer in USA (IV) before April 2023
- 14 Apr 2023 Efficacy and adverse events data from preclinical studies in Gastric and Ovarian cancer released by Catamaran Bio
- 03 Jan 2023 Camaran Bio in-licenses Flow Electroporation® technology and ExPERT™ technology from MaxCyte